A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available

• Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion

• Adequate bone marrow, renal and liver function

Exclusion Criteria:

• Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment

• Patients with known symptomatic brain metastases requiring steroids

• Prior treatment with a compound of the same mechanism